August 2011
London New Drugs Group APC/DTC Briefing To prevent 1 systemic embolism or stroke (including haemorrhagic stroke), 167 patients need to be treated with dabigatran 150mg instead of warfarin for 1 year, this would equate to a spend of £153,640. The estimated hospitalisation costs for an AF patient admitted with a non-fatal stroke and the mean annual costs of stroke after discharge is £16,641.
Commissioner and provider approaches in the pre-NICE period NICE published its preliminary recommendations on 16th August 2011. The Appraisal Committee is minded not to recommend the use of dabigatran etexilate for the prevention of stroke and systemic embolism in people with atrial fibrillation. The Committee requests further information about the licensed regimen, in which people under 80 years begin treatment with dabigatran etexilate 150 mg twice daily, and at 80 years switch to dabigatran etexilate 110 mg twice daily. Boehringer Ingelheim have been asked to provide further information for the second Appraisal Committee meeting in September 2011. The cost effectiveness of dabigatran in comparison to drug and non-drug costs for warfarin needs to be considered carefully. Despite the potential advantage of dabigatran there remain a number of unknowns related to uptake such as the confidence clinicians and patients will have in an anticoagulant for which efficacy cannot be monitored, and the effectiveness in the real world of an anticoagulant for which adherence cannot be determined.
In the period between launch of dabigatran and the publication of a NICE single technology appraisal, various approaches are being taken to manage the introduction of the therapy. These include limiting use to groups including those contraindicated to warfarin (as per the SPC), those unable to take warfarin, and those with poor control (defined as TTR<65%). The cost pressures associated with each approach are being mapped by cardiac networks, but there are a number of generic points: It is possible (but not yet demonstrated) that there could be a reduction in non-drug costs associated with use of the dabigatran. However, the fixed costs associated with anti-coagulation services will remain for the foreseeable future given the need to maintain AF patients stable on warfarin and groups with indications other than AF. A cost of £400 per patient per year is stated by NICE for running anticoagulant clinics in primary/secondary care. The costs may be greater if patients are not stable or have to attend anticoagulant clinics more frequently, although given that block contracts are often in place, this may be an overestimate and actual costs could be significantly less than this. Commissioners and providers have differing views as to whether prescribing for patients pre-NICE should be initiated only in secondary care, or whether tailored introduction is possible in primary care. A significant patient lobby for dabigatran is expected at launch and commissioners and providers need to consider how best to handle this development. Commissioners need to consider how flexibility is built into anticoagulant clinic contracts for next year, so if patients are prescribed dabigatran, money can be extracted from warfarin services (often block contracted) to assist in paying for the increased drug costs. There are also many anticoagulant services in primary care provided either via GP local enhanced services or community health provider services. There are a variety of approaches to managing the use of dabigatran for AF. Any approach which seeks to implement early introduction of dabigatran will cost additional money.
London New Drugs Group APC/DTC Briefing Background Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the UK. More than 46,000 new cases of AF are diagnosed each year. The prevalence of AF increases with age -at 50-59 years of age, the prevalence is around 0.5%, by 80-89 years of age, the prevalence is around 9%. More men than women have AF, when data are adjusted for age. In UK hospitals, 3-6% of people admitted with acute medical conditions have AF. [1] Stroke and thromboembolism are the main complications of AF. People with AF have a five-fold greater risk of stroke and thromboembolism than people without AF. Ischaemic strokes in association with AF are often fatal, and those patients who survive are left more disabled by their stroke and more likely to suffer a recurrence than patients with other causes of stroke. [2] The annual incidence of stroke attributable to AF increases from 1.5% in people 50-59 years of age to 23 In these guidelines they have modified the CHADS 2 criteria to give a more detailed risk assessment. The more refined tool clarifies the most appropriate antithrombotic if the CHADS 2 score is 1. CHA 2 DS 2 -VASc is a risk factor based approach that can be used for patients with non-valvular AF, it can be used in conjunction with CHADS 2 . The score (out of 9) determines whether or not to anticoagulate.
Congestive ' and some caution and regular review of the patient is needed following the initiation of antithrombotic therapy, whether with warfarin or aspirin. Many of the risks for stroke and bleeding are the same, so it is important to separate GI bleeding as a potential risk factor, rather than the HAS-BLED score alone.
In patients with AF, warfarin prevents 64% of strokes, however due to several factors it is prescribed to only two thirds of appropriate candidates. Factors precluding use include drug and dietary interactions, inconvenience of INR monitoring and risk of haemorrhage. [4] Time within the therapeutic INR range (TTR) with warfarin varies widely among individuals, centres and countries. In a posthoc analysis of a clinical trial comparing warfarin with clopidogrel and aspirin involving 526 centres in 15 countries, the mean TTR in the UK centres was 75% (range 46%-78%), however, this study was stopped early. [5] A record linkage study in 1,513 UK patients with nonvalvular AF treated with warfarin for a minimum of 6 months, showed that maintaining an INR within the range 2.0 3.0 for 6 months was only achieved by 52% of patients. [6] A systematic review and meta-analysis looking at the effect of setting, monitoring intensity and patient experience on anticoagulation control worldwide, considered 22 studies where target INR was 2.0 to 3.0 and found the mean TTR was 61.3%. [7] A systematic review and metaregression study reviewed published randomised or cohort clinical trials that measured INRs serially in anticoagulated patients and reported the proportion of time patients spent between within the range 1.8-2.0 and 3.0-3.5. Overall, patients were in their therapeutic range 63.6% of the time (range 61.6 -65.6%). The study authors concluded that patients who receive anticoagulation therapy spend a significant proportion of their time out of the therapeutic range. [8] Antiplatelet treatment with aspirin is much less effective than warfarin, it reduces the risk of stroke by about a fifth compared with placebo. [9] Adding clopidogrel to aspirin improves the effectiveness of antiplatelet treatment to prevent stroke (although the combination remains significantly less effective than warfarin), however the significant increase in major bleeding with the combination is such that it is not recommended routinely within national and Oral anticoagulation, such as warfarin adjusted to INR 2-3 is recommended.
Score is ≥ 1 1 clinically relevant non-major risk factor
Oral anticoagulation or aspirin 75-325mg daily. The preferred choice is to use oral anticoagulation rather than aspirin.
Score is 0 No risk factors
Use either aspirin 75-325mg daily or no antithrombotic therapy. The preferred choice is to use no antithrombotic therapy rather than aspirin.
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London New Drugs Group APC/DTC Briefing international guidance. [10, 11] Current guidelines recommend warfarin for patients with atrial fibrillation at high risk of stroke (previous stroke or embolism or more than one of the following risk factors: age ≥75 years, hypertension, diabetes, or congestive cardiac failure), either aspirin or warfarin for those at moderate risk (only one stroke risk factor), and aspirin for patients at low risk for stroke (no stroke risk factors). [12] Dabigatran etexilate Dabigatran etexilate (as mesilate) is an orally active antithrombotic agent which is a prodrug. It is converted to its active form dabigatran by a serum esterase which is independent of cytochrome P450. Dabigatran is a specific and reversible direct thrombin inhibitor. Thrombin is a key enzyme in blood clot formation at the end of the coagulation cascade. [3, 13, 14] Dabigatran has a half life of 12-14 hours and approximately 85% is excreted by the kidney. [13, 14] Dabigatran etexilate (as mesilate) 75mg and 110mg capsules are already licensed in the UK at doses of 150mg and 220mg once daily for the primary prevention of venous thromboembolic events (VTE) post (elective) total hip and knee replacement surgery but not stroke prevention in patients with AF. [13, 15] [13, 14] The recommended dose of dabigatran is 300mg taken as 150mg twice daily. [14] Patients aged 80 years or above should be treated with 220mg taken as 110mg twice daily due to the increased risk of bleeding in this population. [13] Patients who are concomitantly taking verapamil should also use 110mg twice daily. Dabigatran and verapamil should be taken at the same time. [13] The FDA and Health Canada licensed dabigatran etexilate 150mg but not 110mg for stroke prevention in patients with AF in October and November 2010 respectively. [16, 17] The reasons for the FDA decision were explained in an article in the New England Journal of Medicine in April 2011. The authors summarise all the analyses and considerations that took place and state that the decision to only approve the higher dose was taken because they could not find any subgroup in which use of the lower dose would represent an advantage. [18] The review that the FDA prepared on dabigatran also highlighted that a superiority claim over warfarin should not be granted. This is because there were concerns about granting a superiority claim based on the results of a single, open-label study. Much of the evidence for reduction in stroke/ systemic embolism in the 150 mg arm vs. warfarin arm is driven by subjects at sites with poorer INR control. The review states that although the findings in subjects at centres achieving levels of INR control above the median are still supportive of efficacy, they are not supportive of superiority over warfarin. [17, 19] There is no experience of dabigatran use in children or adolescents, therefore it can not be recommended due to lack of data on safety and efficacy. Women of child bearing potential should avoid pregnancy during treatment with dabigatran. Studies in animals have shown August 2011 London New Drugs Group APC/DTC Briefing reproductive toxicity. There are no clinical data on the effect of dabigatran on infants during breast feeding. Breast feeding should be discontinued during treatment with dabigatran. [13, 14] Use of dabigatran is contraindicated in patients who have -Hypersensitivity to the active substance or to any of the excipients. Severe renal impairment (CrCL <30 ml/min). Active clinically significant bleeding.
An organic lesion at risk of bleeding. Spontaneous or pharmacological impairment of haemostasis. Hepatic impairment or liver disease expected to have any impact on survival.
Concomitant treatment with systemic ketoconazole, cyclosporine, itraconazole or tacrolimus. [13, 14] The Summary of Product Characteristics states there is no antidote to dabigatran. [13, 14] Doses of dabigatran beyond those recommended, expose the patient to increased risk of bleeding. In case of an overdose suspicion, coagulation tests can help to determine a bleeding risk. A calibrated quantitative (dTT) test or repetitive dTT measurements allow prediction of the time by when certain dabigatran levels will be reached, also in case additional measures e.g. dialysis have been initiated. Excessive anticoagulation may require interruption of dabigatran treatment. There is no specific antidote to dabigatran. In the event of haemorrhagic complications, treatment must be discontinued and the source of bleeding investigated. Since dabigatran is excreted predominantly by the renal route adequate diuresis must be maintained. Appropriate supportive treatment, such as surgical haemostasis and blood volume replacement, should be undertaken at the prescrib-ers discretion. As protein binding is low, dabigatran can be dialysed; there is limited clinical experience to demonstrate the utility of this approach in clinical studies. [13, 14, [20] [21] [22] Comments received from reviewers highlighted that warfarin is a safe drug other than the bleeding risk and the reversibility of warfarin can be overemphasised. Often by the time warfarin patients with life threatening bleeding reach hospital, and are given appropriate treatment for reversal, many hours have elapsed.
Two case reports published in Archives of Internal Medicine in July 2011 discuss 2 cases of serious bleeding with dabigatran, one fatal, in low body weight elderly patients. [23] The first case was a woman aged 84, with a body weight of 40kg and poor renal function (CrCl 32ml/min/1.73m2), who was being treated with dabigatran 75mg twice daily for AF; she was also receiving amiodarone. She was admitted with abdominal pain and rectal bleeding, and during the course of her admission developed massive rectal bleeding that was fatal. The second case was also a woman, aged 89, with a body weight of 45kg and CrCL 29 mL/ min/1.73 m 2 . She was admitted for removal of a cochlear implant, but reported a 1-week history epistaxis. The surgery was postponed, dabigatran was stopped, and her outcome was favourable. The authors comment that dabigatran is excreted mainly by the kidneys, thus impaired renal function will cause accumulation and is likely to have resulted in the overdoses in both these patients. They note also that there is an interaction between dabigatran and amiodarone that markedly increases dabigatran bioavailability. Finally, they highlight that there is not currently an easy test for dabigatran overdose and no antagonist available. They suggest a need for great caution in giving dabigatran to elderly patients, and encourage reporting of bleeding events. The primary efficacy endpoint of the trial was incidence of stroke (including haemorrhagic) and systemic embolism. The primary safety endpoint was major bleeding. [26] Over a median two-year follow-up, the study found that the lower dose of dabigatran was non-inferior to warfarin at reducing the risk of stroke and systemic embolism in people with AF. The higher dose was found to be statistically significantly more effective than warfarin. Low dose dabigatran was associated with a reduced risk of major bleeding, whereas there were no significant differences between the high-dose dabigatran and warfarin. A pre-specified substudy of the RE-LY trial compared the results in patients naïve to and experienced with warfarin. 50.4% (9,123) of the trial population were warfarin-naïve and 49.6% (8, 989) were warfarin-experienced. The data showed that for patients starting dabigatran without prior warfarin experience and for those switching from warfarin, there was benefit from dabigatran at either dose compared to warfarin. The rate of the primary efficacy outcome (stroke and systemic embolism) was lower with dabigatran, this was statistically significant with 150mg dabigatran. The rate of the primary safety outcome was also reduced with dabigatran. For the patients assigned to warfarin, TTR was 62% for warfarin naïve patients and 67% for those experienced on warfarin.
Detailed results are set out in table 3. [29] A posthoc analysis of patients who underwent cardioversion in the RE-LY study has been published. Data from before, during and 30 days after cardio-version were analysed. A total of 1983 cardioversions were performed in 1270 patients. Detailed results are set out in table 4. The frequencies of stroke and major bleeding on the 2 doses of dabigatran were low and comparable to those on warfarin with or without transesophageal echocardiography guidance. There was no significant difference in the rate of the primary outcome within 30 days of cardioversion with either dose of dabigatran and warfarin. Dabigatran 110mg significantly reduced the rate of major bleeding whilst the rate of bleeding with dabigatran 150mg was similar to warfarin. The study authors conclude that dabigatran is a reasonable alternative to warfarin in patients requiring cardioversion. [30] A comment from the reviewers highlighted that there is no data for atrial fibrillation ablation with dabigatran. This procedure is normally performed while patients are fully anticoagulated on warfarin as this improves the embolic stroke risk. The NPC review of the RE-LY study provides a critical appraisal of the trial [32] : More patients discontinued treatment with dabigatran than warfarin (21% vs. 17% respectively) during the study, which might be due to poorer tolerability or be due to the open-label trial design. A higher incidence of discontinuations that were a result of serious side effects supports this view (2.7% for both doses of dabigatran and 1.7% for warfarin). However, as patients and physicians knew which treatments (dabigatran or warfarin) were being received this may have raised their perception of possible side effects from the newer drug, and decisions to discontinue may have been taken more readily.
RELY-ABLE is a long term extension of
The results of this study are not directly applicable to those patient groups who were excluded from the study (e.g. those with recent strokes). In general, the patients included, who were at moderate to high risk of stroke, are the types of patients for which warfarin can be considered according to the NICE AF clinical guideline. [34] RE-LY recruited approximately 2% of patients with a CHADS 2 score of 0 and about 30% with a score of 1, as well as patients with a CHADS 2 score of 2 and above. The average CHADS 2 score in RE-LY was 2.1. In the study, the mean time the INR was in the therapeutic INR range was 64%. This is similar to other contemporary trials of warfarin. An analysis looking at the time the INR was in therapeutic range is discussed above. [28] Although, major bleeding was no 
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London New Drugs Group APC/DTC Briefing more frequent between groups overall, the higher risk of GI side effects (both doses) and GI bleeding with dabigatran at the 150mg dose compared with warfarin raises questions about its use in people who are at high risk of these side effects.
The study only considered dabigatran treatment for a median period of two years, and thus long-term safety is not yet known. Serious hepatic side-effects were the reason for the withdrawal of the licence for ximelagatran (another thrombin inhibitor) for a similar indication. There were no indications of a difference between treatments with regard to hepatic side effects in the present study, and use in patients with moderatesevere renal impairment is unclear because patients with a creatinine clearance of less than 30ml/min were excluded. The numerically greater rate of MIs with high-dose dabigatran serves as a signal of potential long-term safety which will need to be considered. The absolute differences in this study were small; nevertheless, this raises particular concerns about the use of dabigatran in people who are at high risk of coronary heart disease. There are approximately 600,000 adults with AF in England, and a substantial number of myocardial infarctions might therefore result from longterm use of dabigatran in place of warfarin. While the mechanism remains to be ascertained, dabigatran has been reported to increase urinary thromboxane excretion in patients not receiving aspirin, suggesting a paradoxical platelet activation effect. Alternatively, the difference could reflect a protective effect of warfarin against MI. [35, 36] The results of substudy of the RE-LY trial presented at the 2011 International Society on Thrombosis and Haemostasis Congress indi-cated that there is no evidence that dabigatran is associated with platelet aggregation in patients with AF. [37] An editorial in the BMJ highlighted that although dabigatran has some benefits over warfarin, evidence on long term efficacy and safety is lacking. [33] A Canadian review of the RE-LY trial published early in 2011 provides a critical appraisal of the data. Based on a number of concerns around absence of blinding in the trial, the increased annualised incidence of intracranial haemorrhage with warfarin and the concomitant use of antiplatelets, the conclusions were -Licensing of dabigatran 150 mg BD for atrial fibrillation is premature, pharmacologically irrational and unsafe for many patients. The optimal dose of dabigatran for non-valvular atrial fibrillation is not yet clear. An independent audit of RE-LY is needed to check for irregularities in conduct, sources of bias and the cause of the unusually high incidence of intracranial haemorrhage in the warfarin arm. In comparable trials with warfarin in AF patients, annualised incidence of intracranial haemorrhage has ranged from 0.28% to 0.53%. An independently conducted doubleblind RCT comparing dabigatran with warfarin in patients with non-valvular atrial fibrillation is required. Taking antiplatelet drugs in combination with oral anticoagulants doubles the incidence of major bleeding events. [17] Although the RE-LY study continued for a median of 2 years, the NNTs have been annualised. The NNTs for twice daily 150mg dabigatran (superior to warfarin) and 110mg dabigatran (noninferior to warfarin) are set out in table 5. [26, 27] August 2011 London New Drugs Group APC/DTC Briefing A systematic literature review and network meta-analysis to synthesise the efficacy and safety data of treatments used in the prevention of stroke and systemic embolism in AF patients was published in 2010. This approach was taken as assessing the safety and efficacy of dabigatran in a head to head study versus aspirin with or without clopidogrel and placebo in a clinical trial would be unethical given the existing evidence base. The statistical analyses calculated NNTs for stroke, systemic embolism, mortality and acute myocardial infarction for dabigatran with other antiplatelet agents and placebo -see table 6 . [38] The results indicate that one stroke of any type will be avoided for every 16, 18 or 19 patients treated with dabigatran 150mg, 110mg and warfarin respectively compared with patients not receiving any stroke prophylaxis. The results show there is indirect evidence that treatment with dabigatran reduces the risk of stroke, systemic embolism and mortality compared with aspirin, aspirin plus clopidogrel and placebo in patients with AF. [38] Guidelines and guidance on use of dabigatran Review of the NICE AF guidance is under discussion and use of dabigatran in England and Wales will be addressed by the NICE single technology appraisal guidance expected by December 2011. NICE will produce criteria for use based on clinical and cost effectiveness. The Appraisal Committee's preliminary recommendations were published on 16 August 2011. [39] In anticipation of dabigatran being licensed and launched, recommendations for the use of dabigatran were incorporated into the most recent European Society of Cardiology updated guidelines for the management of AF -see table 7.
[2] Following a CHADS 2 score of >1 and then a CHA 2 DS 2 -VASc assessment where an oral anticoagulant is recommended, dabigatran may be considered as an alternative to adjusted dose warfarin therapy.
The 2010 Canadian Cardiovascular Society AF guidelines make similar recommendations to the European guidance -see table 8. One major difference is in patients who have stable coronary artery disease. The guidelines state that given the benefits of warfarin for the reduction of coronary events, which can be substantial in those patients at higher risk, when oral anticoagulation is indicated to prevent stroke in those who have AF and are also at high risk of a coronary event (e.g. those without evidence of coronary artery disease whose Framingham risk is 2% per year, those with stable coronary artery disease with high risk features and those with or ACS in recent months) it seems prudent to recommend warfarin in preference to dabigatran. [41] The NHS North East Treatment Advisory Group (NETAG) produced guidance on use of dabigatran for prevention of stroke in non-valvular AF in July 2011. [42] NETAG recommended use for the following patient groups -August 2011 London New Drugs Group APC/DTC Briefing Dabigatran 150 mg twice daily may be considered, in view of the improved efficacy in the prevention of stroke and systemic embolism (but lower rates of intracranial haemorrhage and similar rates of major bleeding events, when compared with warfarin). Measurable risk of bleeding (e.g. HAS-BLED score of >/= 3)
Dabigatran 110 mg twice daily may be considered, in view of a similar efficacy in the prevention of stroke and systemic embolism (but lower rates of intracranial haemorrhage and of major bleeding compared with warfarin). One 'clinically relevant nonmajor' stroke risk factor Dabigatran 110 mg twice daily may be considered, in view of a similar efficacy with warfarin in the prevention of stroke and systemic embolism but lower rates of intracranial haemorrhage and major bleeding compared with the warfarin and (probably) aspirin. No stroke risk factors (e.g. CHA 2 DS 2 -VASc = 0)
Either aspirin 75-325 mg daily or no antithrombotic therapy is recommended. Where possible, no antithrombotic therapy should be considered for such patients, rather than aspirin, given the limited data on the benefits of aspirin in this patient group (i.e. lone AF) and the potential for adverse effects, especially bleeding The Midlands Therapeutics Review and Advisory Committee issued commissioning guidance on the use of dabigatran in August 2011.
[44] Their recommendations are that warfarin remains the first line option for anticoagulation in patients with AF at a high risk of stroke. Commissioners should ensure optimal existing warfarin therapy services including access to INR clinics, use of computerised decision-support software, and access to drugs such as acenocoumarol for patients allergic to warfarin. In view of the considerable financial implications, dabigatran treatment should only be prescribed for -Those patients with co-morbidities who are adherent to warfarin monitoring and lifestyle requirements but need frequent coprescribed medications that interact with warfarin and affect the patients TTR.
Those patients who are adherent to monitoring and lifestyle requirements but whose TTR remains unacceptable despite attempts to optimise treatment with warfarin. Commissioners should set the TTR threshold at an affordable level for their local health economy.
Budgetary implications
The cost per day is £2.52. The annual cost per patient is £920. The authors of the document highlight that there are a number of limitations -the analysis is based on subgroup analyses using point estimates for secondary endpoints, together with one way sensitivity analyses. The measure of warfarin control, TTR, is taken as a measure of the clinical effectiveness of warfarin, however, it may reflect differences in overall care between centres. The impact of institutional factors was not addressed but could be very important. Numerous assumptions were made to generalise the data from two clinical studies to the English AF population. [45] As dabigatran does not require regular anticoagulant monitoring, there could be a reduction in non-drug costs associated with use of the medicine. However, what is uncertain is if dabigatran will require additional consultation time to ensure that patients understand the need to adhere to therapy. Should specific patient education take place during a normal GP consultation or would this be in the context of an anticoagulant clinic and what would the costs of this be? Good patient information and counselling are crucial with warfarin and this will also apply to dabigatran especially in relation to the lack of long term safety data and uncertainty around reversibility. The costs associated with the current warfarin service will continue due to the need to maintain the existing infrastructure for patients well established on warfarin. Warfarin and anticoagulant clinics will still be required as warfarin has a number of uses aside from atrial fibrillation. The following indications include treatment of deep-vein thrombosis and pulmonary embolism, cardioversion, dilated cardiomyopathy, mural thrombus, coronary artery thrombosis, paroxysmal nocturnal haemoglobinuria as per recommendations by the British Society for Haematology. [47, 48] One view is that it seems unlikely that there will be real cost savings until the evidence for alternatives to warfarin becomes more established. [32] The prevalence of AF is about 1,300 per 100,000 population. The NICE clinical guideline on AF estimated that about 47% of people with AF receive anticoagulant therapy (611/100,000) however another 30% (390/100,000) are eligible for therapy but do not receive treatment. [34] The average cost of running primary/secondary care anticoagulant clinics is approximately £400 per annum per patient. [34, 49] There are data that says the setting and model of an anticoagulant clinic plays a big part in the quality and level of anticoagulant control achieved by patients, commissioners need to decide locally how much of the work in introducing dabigatran appropriately is around providing support to clinics achieving lower levels of anticoagulation control, redesigning services and patient pathways, dispelling myths around warfarin use and improving uptake of warfarin to manage their budget. Dabigatran is unlikely to be the solution for poorly performing clinics or non-adherent patients.
Based on the figures above, the following may apply: Current annual expenditure on AF patients at risk of stroke -611 per 100,000 population on warfarin at a cost of £14/yr = £8,554, 611 people attending an anticoagulant clinic = £244,400, Total costs are therefore approximately £250,000 (£409 per patient). If the additional 30% of patients with AF who are currently not receiving treatment were to receive warfarin, the extra cost would be about £161,400. If they received dabigatran instead, the increase in annual expenditure would be around £358,000 based in a fully compliant patient. However, this figure does not include the off-set of acute care costs for stroke, rehabilitation and disability.
To prevent 1 systemic embolism or stroke (including haemorrhagic stroke), 167 patients need to be treated with dabigatran 150mg instead of warfarin for 1 year, this would equate to expenditure of £153,640. This figure does not include the potential savings through the prevention of acute events nor subsequent rehabilitation and disability costs or cost reduction due to withdrawals from dabigatran.
The West Yorkshire Cardiac Network economic appraisal estimated the costs for non-fatal stroke and other events in AF patients -see table 10 . [45] The estimated hospitalisation costs for an AF patient admitted with a non-fatal stroke and the mean annual costs of stroke after discharge is £16,641.
Commissioners need to consider how flexibility is built into anticoagulant clinic contracts so if patients are prescribed dabigatran, money can be extracted from warfarin services (often block contracted) to assist in paying for the increased drug costs. A reduction in the number of people attending anticoagulant clinics in the short term is not anticipated. As well as anticoagulant clinics in acute hospital trusts, there are also many anticoagulant services in primary care provided either via GP local enhanced services or community health provider services.
Commissioners need to plan to control the introduction of the medicine as patient and clinician expectations are already high and any approach which seeks to implement early introduction of dabigatran will cost additional money. 
